TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02194101

Intervention type: PROCEDURE
Intervention: Supernormal oxygen delivery goal therapy
Description: A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
Study: NCT03802838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
Study: NCT03802838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride
Description: Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
Study: NCT03709719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Injection
Description: Blinatumomab 28 μg/day : D1 to D28
Study: NCT02669550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope
Description: In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposcope endoscope
Description: In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
Study: NCT02324842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Study: NCT01378195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based program for dementia caregivers
Description: Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
Study: NCT00588328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: PET/CT scans
Study: NCT01378195

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational/Resources program
Description: Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
Study: NCT00027820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo nonmyeloablative PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative PBSCT
Study: NCT04149028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml
Description: intraovarian injection of 2 mml of PRP by laparoscopic guide
Study: NCT04065568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKO-tool
Description: The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
Study: NCT01946984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopy, retrograde cholangio-pancreaticography.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP
Description: endoscopy, retrograde cholangio-pancreaticography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01185028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide With Pegylated Interferon And Ribavirin
Description: Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
Study: NCT02188082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IvabRadine hemisulfate Sustained-release Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04086641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover foot
Description: A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossover foot
Description: A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy Storing Foot
Description: A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy Storing Foot
Description: A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
Study: NCT00027820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study: NCT02155374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sliding scale insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate acting insulin
Study: NCT01047995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir plus Darunavir/ritonavir
Description: Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir plus Darunavir/ritonavir
Description: Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.
Study: NCT02709993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
Study: NCT00988741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is provided in a capsule form.
Study: NCT02279524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol
Description: Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study.
Study: NCT03509207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Oral Capsule
Description: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
Study: NCT04676464

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra- sound
Description: Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
Study: NCT01043185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 30 mg orally in the morning and 30 mg in the evening for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 90 mg orally in the morning and 90 mg in the evening for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 120 mg orally in the morning and 120 mg in the evening for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 240 mg orally in the morning and 240 mg in the evening for 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
Study: NCT02891798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)
Description: Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Only (control arm)
Description: Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
Study: NCT04389749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM
Description: CPM-continuous passive motion device.
Study: NCT03033849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing Contour® Next One
Description: This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing FreeStyle Freedom Lite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing OneTouch® Verio

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system for self-testing GlucoMen® areo
Study: NCT01570400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered cognitive behavioral therapy (iCBT)
Description: Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered cognitive behavioral therapy (iCBT)
Description: Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 1
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 2
Description: Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks.
Study: NCT01838174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel (ACTH)
Description: 15 days of daily injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV methylprednisolone (steroids)
Description: 3 days of intravenous methylprednisolone followed by 11 days of oral taper
Study: NCT02590445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation system
Study: NCT01158833

Intervention type: OTHER
Intervention: classification of gait in diplegic children with CP
Description: To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
Study: NCT01520415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
Study: NCT03009539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Primary Care
Description: The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family.
Study: NCT02892370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 tablets (10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 tablets (10 mg)
Study: NCT00970398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula supplemented with bovine milk Osteopontin
Description: Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula supplemented with bovine milk Osteopontin
Description: Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Infant formula without supplementation of bovine milk Osteopontin
Study: NCT01862003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
Study: NCT02309164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 10 acupuncture sessions of 30 minutes each, twice a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation group
Description: medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Orientation group
Description: medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
Study: NCT03151148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMT Lotion
Description: TMT product and Vegetable glycerin-Cetaphil®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Cetaphil® moisturizing lotion and vegetable glycerin
Study: NCT01628016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a word dot-probe task for training procedure
Description: In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
Study: NCT05010057

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Placebo capsules containing microcrystalline cellulose
Study: NCT01613300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab as part of the reduced intensity conditioning regimen (RIC)